BUY Cipla Ltd. — Arun Kumar Mantri
byArun Kumar MantriHorizon: 1 year28 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·21 Sept · 1w ago
Wockhardt Share Price Today: 2.19% rise and sector view
NewsGoogle News·17 Sept · 2w ago
Kopran Ltd. Share Price Rises 8.83% Today
NewsGoogle News·15 Sept · 2w ago
Explained: Why Morgan Stanley has the second-lowest price target on the Street for this drugmaker
NewsCnbc-Tv18·4 Sept · 4w ago
Cipla announces exclusive US partnership with Qilu Pharma for keytruda biosimilar
NewsCnbc-Tv18·3 Sept · 4w ago
Q2 FY27 results scheduled — board meets 27 Oct 2026
BSE · Board Meeting·In 27 days
ICICI Lombard, United Breweries And Cipla: Three Stocks That Bucked The Trend As Stock Market Crashed
NewsNdtv-Profit·24 Sept · 6d ago
Anthem Biosciences Share Price Today: valuation and peers
NewsGoogle News·18 Sept · 2w ago
SYMBIOTEC Share Price News: price rise and valuation view
NewsGoogle News·18 Sept · 2w ago
Cipla Ltd is intimating shareholders and creditors about a notice regarding a Scheme of Amalgamation (by Absorption) of Inzpera Healthsciences Limited with Cipla Limited. The notice provides an opport
BSE · Company Update·3 Sept · 4w ago
Long-term trend bearish — 200-day average falling over the past quarter
Technicals · trend·29 Sept · yesterday
US Drug Tariff: 15 Pharma Stocks Likely to Be Impacted by Trump’s New Tariff Plan
NewsGoogle News·16 Sept · 2w ago
Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field
NewsHbl·4 Sept · 4w ago
3 other SEBI-registered advisors have active long-term SELL calls on this stock
Advisor consensus · same horizon·24 Jul · 2mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.